Recrystallize in orbit
Blockbuster APIs are recrystallized in microgravity, where mass transport is governed by pure diffusion — no buoyancy-driven defects.
Real pharma IP. Grown in orbit.
Orbital manufacturing
for the future
of pharmaceuticals.
We remove the physical limits that gravity imposes on crystallization. In microgravity we grow superior drug crystal polymorphs that cannot exist on Earth — and we hold the patents on them. Flight hardware is built, partners are contracted, and our first payload flies in Q1 2027.
- $260B+addressable patent cliff (2025–2030)
- Q1 2027first payload to orbit · Isar / Andøya
- AUD 2.5Mnon-dilutive government R&D grant secured
01 — The thesis
Big Pharma is staring down the largest patent cliff in history.
Between 2025 and 2030, blockbuster drugs generating over $260B in annual revenue lose exclusivity. The molecules stay valuable; the monopolies protecting them expire.
Superior crystalline polymorphs unlock fresh patents and the FDA 505(b)(2) pathway. The catch: on Earth, gravity disrupts crystallization. In orbit, it doesn’t — so the next generation of these patents will not be filed in a terrestrial lab. We intend to hold them.
02 — The technology
Orbital microgravity. Earth-impossible polymorphs.
Isolate new polymorphs
We isolate and stabilize entirely new, superior crystalline forms that are unachievable under Earth's gravity.
Patent & file 505(b)(2)
Each new polymorph supports a fresh patent filing and the FDA 505(b)(2) regulatory pathway — extending market exclusivity.
Own the exclusivity
The superior form is ours, protected by our filings. Anyone who wants it — incumbents included — licenses it from us, on our terms.
01
CrystallizeSamara capsule, microgravity, diffusion-governed growth
02
ReturnRe-entry and recovery, Koonibba Test Range
03
CharacterizeSynchrotron MX, XRD / TGA / DSC
04
ProtectPatent filings and FDA 505(b)(2)
03 — Hardware & partnerships
Contracted, funded, and built — not promised.
Isar Aerospace Launch
NDA + Launch Services Agreement (draft) on the Spectrum vehicle.
Southern Launch Recovery
Range agreement & NDA in negotiation — Koonibba Test Range, Australia, for re-entry recovery.
ANSTO — Australian Synchrotron Science
NDA executed. Macromolecular validation on the synchrotron MX beamlines (Australian Government facility).
CCDC, Cambridge Science
Data-exchange terms agreed for polymorphic validation & predictive modeling.
Univ. of Western Australia Science
CDA executed — post-flight XRD / TGA / DSC characterization.
NASA LunaRecycle Award
Challenge winner 2024 & 2025 — NASA Centennial Challenges hardware competition.
AUD 2.5M grant Funding
Non-dilutive Australian Government grant secured for R&D.
04 — Mission 2027
Payload capacity is allocated, not sold.
Capacity on our first 2027 mission is allocated strictly to strategic partners. A limited number of payload slots is available for exclusive licensing, including Right of First Refusal on the polymorphs and filings arising from that slot.
- Exclusive licensing terms negotiated per slot
- Right of First Refusal on resulting IP
- Full characterization data package post-flight
- Co-development and joint filing options available